{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T05:21:51Z","timestamp":1761974511704,"version":"build-2065373602"},"reference-count":10,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaci-inpractice.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Allergy and Clinical Immunology: In Practice"],"published-print":{"date-parts":[[2019,1]]},"DOI":"10.1016\/j.jaip.2018.05.005","type":"journal-article","created":{"date-parts":[[2018,5,23]],"date-time":"2018-05-23T21:27:44Z","timestamp":1527110864000},"page":"300-302","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Use of omalizumab in uncontrolled chronic spontaneous urticaria also improved latex-induced contact urticaria"],"prefix":"10.1016","volume":"7","author":[{"given":"Elisabetta","family":"Di Leo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gianfranco","family":"Calogiuri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luigi","family":"Macchia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eustachio","family":"Nettis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaip.2018.05.005_bib1","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1111\/all.13397","article-title":"The EAACI\/GA2LEN\/EDF\/WAO Guideline for the definition, classification, diagnosis and management of urticaria. The 2017 revision and update","volume":"7","author":"Zuberbier","year":"2018","journal-title":"Allergy"},{"key":"10.1016\/j.jaip.2018.05.005_bib2","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1080\/14712598.2018.1438406","article-title":"Effectiveness of omalizumab in adolescent and adult patients with chronic idiopathic\/spontaneous urticaria: a systematic review of \u201creal-world\u201d evidence","volume":"18","author":"Bernstein","year":"2018","journal-title":"Expert Opin Biol Ther"},{"key":"10.1016\/j.jaip.2018.05.005_bib3","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1111\/j.1365-2133.2006.07738.x","article-title":"Double-blind, placebo-controlled study of sublingual immunotherapy in patients with latex-induced urticaria: a 12-month study","volume":"156","author":"Nettis","year":"2007","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaip.2018.05.005_bib4","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1046\/j.1365-2222.2002.01308.x","article-title":"Type I allergy to natural rubber latex and type IV allergy to rubber chemicals in health care workers with glove-related skin symptoms","volume":"32","author":"Nettis","year":"2002","journal-title":"Clin Exp Allergy"},{"author":"L'Agenzia Italiana del Farmaco","key":"10.1016\/j.jaip.2018.05.005_bib5"},{"key":"10.1016\/j.jaip.2018.05.005_bib6","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1007\/s12016-015-8490-y","article-title":"Off-label uses of omalizumab","volume":"50","author":"El-Qutob","year":"2016","journal-title":"Clin Rev Allergy Immunol"},{"key":"10.1016\/j.jaip.2018.05.005_bib7","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1111\/all.13083","article-title":"Mechanisms of action that contribute to efficacy of omalizumab in chronic spontaneous urticaria","volume":"72","author":"Kaplan","year":"2017","journal-title":"Allergy"},{"key":"10.1016\/j.jaip.2018.05.005_bib8","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1016\/j.jaci.2017.06.032","article-title":"Omalizumab treatment in patients with chronic inducible urticaria: a systematic review of published evidence","volume":"141","author":"Maurer","year":"2018","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2018.05.005_bib9","first-page":"143","article-title":"Disappearance of severe oral allergy syndrome following omalizumab treatment","volume":"49","author":"Asero","year":"2017","journal-title":"Eur Ann Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2018.05.005_bib10","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/j.jaci.2004.06.032","article-title":"Omalizumab-induced reductions in mast cell FceRI expression and function","volume":"114","author":"Beck","year":"2004","journal-title":"J\u00a0Allergy Clin Immunol"}],"container-title":["The Journal of Allergy and Clinical Immunology: In Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213219818303271?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213219818303271?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T05:15:40Z","timestamp":1761974140000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2213219818303271"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1]]},"references-count":10,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,1]]}},"alternative-id":["S2213219818303271"],"URL":"https:\/\/doi.org\/10.1016\/j.jaip.2018.05.005","relation":{},"ISSN":["2213-2198"],"issn-type":[{"type":"print","value":"2213-2198"}],"subject":[],"published":{"date-parts":[[2019,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Use of omalizumab in uncontrolled chronic spontaneous urticaria also improved latex-induced contact urticaria","name":"articletitle","label":"Article Title"},{"value":"The Journal of Allergy and Clinical Immunology: In Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaip.2018.05.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 American Academy of Allergy, Asthma & Immunology","name":"copyright","label":"Copyright"}]}}